Vorapaxar: A new class of drug

Abstract

Antiplatelet therapy is the major concern in secondary prevention of ischemic cardiovascular complications. But the failure of combined antiplatelet therapy led to the development of new class of antiplatelet drugs. Vorapaxar is a novel, competitive PAR-1 inhibitor. This present review summarizes the pharmacology of vorapaxar.